Abstract:Objective To enhance the understanding of fulminant type 1 diabetes (FT1 DM). Methods Clinical and laboratory data of 3 patients diagnosed as FT1 DM in our hospital from January 2007 to March 2008 were retrospectively analyzed. Results (1) All of 3 cases were males aged from 29 to 43 years old with body mass index ranged from 21.5 to 23.3 kg/m2. (2)They were developed to ketoacidosis rapidly after the appearance of diabetic symptoms in 2-4 days. One case had a cardiac arrest. (3) At the stage of onset, the plasma glucose level were above 38 mmol/L, glycosylated hemoglobin ranged from 6.2% to 6.3% and serum glycated albumin ranged from 15% to 24%. (4) Serum glutamic acid deearboxylase antibody and protein tyrosine phosphatase antibody were negative. (5) Their β-cell functions were extremely poor confirmed by a standard test meal and arginine stimulation test. (6) Serum hemodiastase (263-2319 U/L) and lipase (812-859 U/L) were high. Ultrasound and computed tomography showed a normal pancreas. (7) Serum creatinekinase level (1283-12 239 U/L) was extremely high. One case had rhabdomyolysis confirmed by biopsy at gastrocnemius muscle. Serum liver enzyme and myocardial enzyme pedigree were risen significantly. (8) Case 1 was treated with multiple daily insulin injections (MDI) when he was discharged. Case 2 was treated with continuous subcutaneous insulin infusion (CSII). Case 3 was treated with MDI at the beginning of the therapy and transferred to CSII later. Comparing glycemic parameters of continuous glucose monitoring, not only mean level of 24 h blood glucose and intra-day giycemic variability (mean amplitude of giycemic excursions and Schlichtkrull's M-value) but also day-to-day glycemic variability (absolute means of daily differences) were indicated case 2 < case 3 (CSII) < case 1 < case 3 (MDI). Conclusions (1) FT1 DM patients had clinical feathers of abrupt onset, serious metabolic disorders, serious impaired islet β-cell function, complicated with multiple organ impair, which required special attention by all medical practitioners. (2) FTI DM patients had a great glycaemia excursion and were subject to hypoglycaemia. Maybe long-term CSII regimen was needed to improve the prognosis.

Fulminant Type 1 Diabetes Mellitus Accompanied by Positive Conversion of Anti-insulin Antibody after the Administration of Anti-CTLA-4 Antibody Following the Discontinuation of Anti-PD-1 Antibody

Type 1 diabetes mellitus affected by potential toxicity from long-term use of nivolumab

Fulminant Type 1 Diabetes Mellitus Exhibits Distinct Clinical and Autoimmunity Features from Classical Type 1 Diabetes Mellitus in Chinese

Anti-PD-L1 therapy and the onset of diabetes mellitus with positive pancreatic autoantibodies

Clinical and Immunological Characteristics of PD-1 Associated Fulminant Type 1 Diabetes Mellitus

Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.

Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event

[Immunological Features of Fulminant Type 1 Diabetes].

Anti PD-1 Monoclonal Antibody Induced Autoimmune Diabetes Mellitus: a Case Report and Brief Review

Fulminant Type 1 Diabetes:The Clinical Features and Treatment Strategy

The Feature, Diagnosis, and Treatment of Fulminant Type 1 Diabetes

Anti-programmed Cell Death Protein-1 Therapy in Intrahepatic Cholangiocarcinoma Induced Type 1 Diabetes: A Case Report and Literature Review

Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study

Natural Killer Cells Modulate Overt Autoimmunity to Homeostasis in Nonobese Diabetic Mice after Anti-CD3 F(ab′)2 Antibody Treatment through Secreting Transforming Growth Factor-β

Immune checkpoint inhibitor-associated myocarditis and fulminant type I diabetes in a patient with metastatic non-small cell lung cancer

C-Peptide-Positive, Autoantibody-Negative Type 1 Diabetes Mellitus

Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report

Characterization of Immune Checkpoint Inhibitor-Associated Fulminant Type 1 Diabetes Associated with Autoantibody Status and Ethnic Origin

Insulinoma presenting with anti-insulin antibodies

Immune checkpoint inhibitor-related type 1 diabetes mellitus which develops long after treatment discontinuation: a case report and review of literature

Pembrolizumab-induced type 1 diabetes